SPRY
HealthcareARS Pharmaceuticals, Inc.
$10.97
$-0.52 (-4.53%)
Jan 5, 2026
Price History (1Y)
Analysis
ARS Pharmaceuticals, Inc. is a biotechnology company listed in the healthcare sector with a market capitalization of $1.08 billion and 162 employees. The company operates in the biotechnology industry. Financially, ARS Pharmaceuticals has reported significant revenue growth at 1471.6% year-over-year, but this growth has not translated to profitability as indicated by negative net income and EBITDA figures. The company's gross margin is 80.5%, operating margin is -163.7%, and profit margin is -56.1%. On the balance sheet, ARS Pharmaceuticals has $288.21 million in cash and $169.80 million in debt, resulting in a debt-to-equity ratio of 115.00. ARS Pharmaceuticals' valuation metrics include a forward P/E of -8.13 and an EV/EBITDA of -23.98, indicating potential concerns regarding the company's financial performance. The price to book is 7.34 and the price to sales is 7.60.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.
Visit website →Key Statistics
- Market Cap
- $1.08B
- P/E Ratio
- N/A
- 52-Week High
- $18.90
- 52-Week Low
- $6.66
- Avg Volume
- 1.93M
- Beta
- 0.74
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 162